NCT07374406

To Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers

A Randomized, Open-label, Single Dose, 2x2 Crossover Study to Evaluate the Safety and Pharmacokinetic Characteristics After Administration of Epaminurad in Healthy Adult Volunteers Under Fasting Conditions

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 34 (estimated)
• Sponsor: JW Pharmaceutical · Industry
• Sex: All
• Age: 19 Years – 55 Years
• Healthy volunteers: Accepted

Summary

A randomized, open-label, single dose, 2x2 crossover study to evaluate the safety and pharmacokinetic characteristics after administration of Epaminurad in healthy adult volunteers under fasting conditions

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Epaminurad 9 mg (JW Pharmaceutical)	Test product. A single oral dose of 1 tablet containing 9 mg of Epaminurad.
DRUG	Epaminurad 9 mg (Shanghai STA Pharmaceutical)	Reference product. A single oral dose of 1 tablet containing 9 mg of Epaminurad.

Timeline

• Start date: 2026-01-14
• Primary completion: 2026-04-19
• Completion: 2026-04-19
• First posted: 2026-01-28
• Last updated: 2026-01-28

Locations

1 site across 1 country: South Korea